Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 240

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial

Open access
Shieh, Yiwey, Eklund, Martin, Madlensky, Lisa, Sawyer, Sarah D., Thompson, Carlie K., Stover Fiscalini, Allison, Ziv, Elad, van’t Veer, Laura J., Esserman, Laura J., Tice, Jeffrey A. · 2017 · Journal of the National Cancer Institute

Abstract

Ongoing controversy over the optimal approach to breast cancer screening has led to discordant professional society recommendations, particularly in women age 40 to 49 years. One potential solution is risk-based screening, where decisions around the starting age, stopping age, frequency, and modality of screening are based on individual risk to maximize the early detection of aggressive cancers and minimize the harms of screening through optimal resource utilization. We present a novel approach to risk-based screening that integrates clinical risk factors, breast density, a polygenic risk score representing the cumulative effects of genetic variants, and sequencing for moderate- and high-penetrance germline mutations. We demonstrate how thresholds of absolute risk estimates generated by our prediction tools can be used to stratify women into different screening strategies (biennial mammography, annual mammography, annual mammography with adjunctive magnetic resonance imaging, defer screening at this time) while informing the starting age of screening for women age 40 to 49 years. Our risk thresholds and corresponding screening strategies are based on current evidence but need to be tested in clinical trials. The Women Informed to Screen Depending On Measures of risk (WISDOM) Study, a pragmatic, preference-tolerant randomized controlled trial of annual vs personalized screening, will study our proposed approach. WISDOM will evaluate the efficacy, safety, and acceptability of risk-based screening beginning in the fall of 2016. The adaptive design of this trial allows continued refinement of our risk thresholds as the trial progresses, and we discuss areas where we anticipate emerging evidence will impact our approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djw290

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 240

Metadata

Authors
Shieh, Y., Eklund, M., Madlensky, L., Sawyer, S. D., Thompson, C. K., Stover Fiscalini, A., Ziv, E., van’t Veer, L. J., Esserman, L. J., & Tice, J. A.
Venue
Journal of the National Cancer Institute
Published
2017-01
Volume
109
Issue
5
Pages
djw290
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2580193500
Cited by
240
References
8
FWCI
15.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. https://app.cochat.ai/papers/10.1093/jnci/djw290
The paper
Shieh, Y., Eklund, M., Madlensky, L., Sawyer, S. D., Thompson, C. K., Stover Fiscalini, A., Ziv, E., van’t Veer, L. J., Esserman, L. J., & Tice, J. A. (2017). Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djw290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.